AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Palo Alto Networks CEO: “We’re happy Wiz is now part of Google, it gives us more room to operate”
2
Cyera raises $400 million at $9 billion valuation in Blackstone-led round
3
Vega raises $120 million Series B as two-year-old cyber startup hits $700 million valuation
4
“Younger people are getting cancer more and more. We have to make kinder medicines.”
5
UAE reportedly behind Elbit’s record $2.3 billion defense deal
More news

Teva

20 stories about Teva
לוגו ctech

CTech’s Daily Israeli Tech News Roundup

26.11.17|CTech
Amazon plans to set up a shipping center in Israel. Israeli parliamentarian criticizes Israeli arms export policy.
מפעל טבע הר חוצבים ירושלים

Mylan's Chairman was Right

26.11.17|Sophie Shulman
In a 2015 letter, Robert J. Coury forecasted Teva’s current troubles
מנכ"ל טבע החדש קור שולץ 2

Israeli Parliamentarians to Push Against Teva Layoffs in the Country

26.11.17|Dror Reich and Maayan Manela
Shelly Yachimovich, a member of the Israeli parliament representing the Israeli Labor Party, said she intends to call an emergency hearing of the Israeli parliament’s state control committee on the issue. The planned layoffs are a result of the company’s management failures, she added
לוגו ctech

CTech's Weekly Israeli Tech News Roundup

24.11.17|CTech
Teva to axe over 4,000 employees. Hedge fund warns it may push to replace board at chip company Mellanox. Big Tech bails on Israeli Treasury party
לוגו ctech

CTech’s Daily Israeli Tech News Roundup

23.11.17|CTech
Teva’s troubles lead to more employee cuts and Periggo completes the sale of its business unit in Israel, but Dutch cannabis is joining the kibbutz. Also, Israel’s private eyes say Black Cube broke the rules.
מנכ"ל טבע החדש קור שולץ 2

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
default image

Allergan to Sell Teva Shares to J.P. Morgan

14.11.17|Dror Reich and Lilach Baumer
Allergan announced it pledged its 9.8% stake in Teva to J.P. Morgan as collateral, as part of a loan agreement. The company already agreed to sell a quarter of the stock in the first quarter of 2018
אננס אננסים

MediWound Loses Stock Purchase Agreement Case

14.11.17|Dror Reich
The burn and wound treatment company was ordered to follow through on previous agreement to buy shares of biotech company Polyheal
מדענית ב מעבדת אבטחת איכות של חברת טבע TEVA

JPMorgan Downgrades Teva’s Stock to Underweight

13.11.17|Amarelle Wenkert
Christopher Schott, managing director at JPMorgan, said that the decision to downgrade is based on the challenges facing Teva’s generic drug unit
default image

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
ראג'יב מאליק נשיא מיילן

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich
Mylan is currently the highest valued company on the TASE at $18.5 billion
מטה טבע פתח תקווה

Fitch Downgrades Teva to Junk Rating

07.11.17|Yaniv Rahimi
The U.S. credit agency changed Teva's rating from BBB to BB, with a negative outlook, due to "significant operational stress." The downgrade might affect Teva's ability to take on additional debt
מפעל טבע נתניה

There May Be a Silver Lining to Teva’s Woes

06.11.17|Eli Shimony
Analysts have lowered their target price for Teva following the company's less than stellar third quarter reports, but the company can still turn its luck around with new drugs and a willingness to tighten the belt
מנכ"ל טבע החדש קור שולץ 2

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer
Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative
קור שולץ מנכ"ל טבע החדש

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
מטה טבע פתח תקווה

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
default image

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
מנכ"ל טבע החדש קור שולץ

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
מפעל חברת טבע הר חוצבים ירושלים

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
מטה טבע פתח תקווה

Teva Offloads Holdings in Australia’s Mesoblast

25.10.17|Dror Reich and Lilach Baumer
The stem-cell therapy company diluted Teva’s shares through a new offering in August
Previous ArticlesMore Articles